Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: Semin Arthritis Rheum. 2014 Feb 11;44(1):47–54. doi: 10.1016/j.semarthrit.2014.02.002

Table 3.

Studies of fracture associated with glucocorticoid therapy

References Condition, n GC inclusion requirement Spine imaging Results Quality score
Stewart et al. [27] JDM, n = 15 GC not required, but all had prior or current use None Clinical incidence 5/15 (33%) 19/23
van Staa et al. [28] Any illness, n = 37,562 Any GC use None Clinical incidence 746/37,562 (2%) 18/22
Rodd et al. [26] Rheumatic diseases, n = 118 GC onset within 30 days of study entry Baseline and 1 year Radiographic incidence 7/118 (6%) 15/18
Loftus et al. [30] JIA, n = 29 ≥ 1 year of GC therapy at a dose of ≥ 5 mg/day Once Radiographic prevalence 13/29 (45%) 17/27
Incidence 3/31 (10%)
Nakhla et al. [31] Rheumatic diseases, n = 49 Prior or current exposure to GC or methotrexate Once Radiographic prevalence 14/49 (29%) 19/23
Varonos et al. [32] JIA, n = 46, ½ with fracture ≥ 1 year of GC therapy, mean dose ≥ 5 mg/day Yearly Higher mean GC dose in those with fracture 13/22

JDM = juvenile dermatomyositis; GC = glucocorticoid therapy; JIA = juvenile inflammatory arthritis.